Indoxacarb

Dr. Kaveh Kahen, Appointed President at Phenomenex

Retrieved on: 
Thursday, February 1, 2024

TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.

Key Points: 
  • TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.
  • Dr. Kahen returns to the Danaher Life Sciences platform with a wealth of experience.
  • He began his career at SCIEX and was responsible for designing and developing novel technologies and instruments.
  • Kaveh is renowned for driving profitable growth in the highly competitive life sciences, analytical testing, and lab equipment markets.

Dr. Kaveh Kahen, Appointed President at Phenomenex

Retrieved on: 
Thursday, February 1, 2024

TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.

Key Points: 
  • TORRANCE, Calif., Feb. 1, 2024 /PRNewswire/ -- Phenomenex Inc., a global leader in the research and manufacturing of advanced separation science and technologies, proudly announces Dr. Kaveh Kahen's appointment as the company's President.
  • Dr. Kahen returns to the Danaher Life Sciences platform with a wealth of experience.
  • He began his career at SCIEX and was responsible for designing and developing novel technologies and instruments.
  • Kaveh is renowned for driving profitable growth in the highly competitive life sciences, analytical testing, and lab equipment markets.

PHARMACEUTICS INTERNATIONAL ONBOARDS NEW LEADERSHIP TEAM TO DRIVE QUALITY, OPERATIONAL IMPROVEMENTS, AND GROWTH

Retrieved on: 
Monday, March 20, 2023

For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.

Key Points: 
  • For over twenty-five years, the company has been providing technical and regulatory capabilities and Pharmaceutics Know-How™.
  • Under Fowlers’ leadership, Pii will focus on the highest level of customer service.
  • Supporting Devan in his expanded role is Sara Frederick, who has joined Pii as Senior Director of Business Operations.
  • He has worked in many HR leadership roles in the medical technology space including Olympus and Thermo Fisher Scientific.

The Worldwide Mass Spectrometer Industry is Projected to Reach $6.2 Billion by 2027

Retrieved on: 
Thursday, July 14, 2022

The Global Mass Spectrometer Market is estimated to be USD 4.44 Bn in 2022 and is projected to reach USD 6.29 Bn by 2027, growing at a CAGR of 7.2%.

Key Points: 
  • The Global Mass Spectrometer Market is estimated to be USD 4.44 Bn in 2022 and is projected to reach USD 6.29 Bn by 2027, growing at a CAGR of 7.2%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Mass Spectrometer Market stakeholders.
  • The report presents a detailed Ansoff matrix analysis for the Global Mass Spectrometer Market.
  • Based on the SWOT analysis conducted on the industry and industry players, The analyst has devised suitable strategies for market growth.

ADAMA Commences In-House Production of Indoxacarb with New Proprietary Synthesis Process

Retrieved on: 
Tuesday, June 21, 2022

ADAMA has launched a number of unique mixtures and formulations based on Indoxacarb, which deliver significant pest control in a variety of affected crops and countries.

Key Points: 
  • ADAMA has launched a number of unique mixtures and formulations based on Indoxacarb, which deliver significant pest control in a variety of affected crops and countries.
  • "With its vast global market potential, we identified Indoxacarb as a key building block for ADAMA's future differentiated product pipeline," said Elad Shabtai, EVP Global Operations at ADAMA.
  • "This new in-house production capability of Indoxacarb is expected to improve the Company's control over the availability, quality and cost of this important active ingredient.
  • The adopted process is based on ADAMA patent protected chemistry affording higher purity and improved process yields.